<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560312</url>
  </required_header>
  <id_info>
    <org_study_id>Charles University</org_study_id>
    <nct_id>NCT01560312</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Refractory Hypertension</brief_title>
  <acronym>PRAGUE-15</acronym>
  <official_title>Renal Denervation - Hope for Patients With Refractory Hypertension?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiocenter Podlesí, Trinec, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open, multicenter, randomized study is enrolling patients in 3 sites in Czech Republic.
      Patients with refractory hypertension will be randomized in 1:1 manner either to renal
      denervation plus optimal medical antihypertensive treatment without spironolactone or to
      antihypertensive treatment alone including spironolactone if not contraindicated. The primary
      end-point is change in Systolic and Diastolic Blood Pressure (BP) between baseline and 1 year
      after randomization evaluated by 24-hours BP monitoring. Expected enrollment is 120 patients.
      Patients follow-up is planned for 3 years.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on analysis of our data after the Symplicity-3 trial announcement, decision for study
    termination was done.
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure difference</measure>
    <time_frame>6 months</time_frame>
    <description>Systolic and Diastolic blood pressure difference between baseline and 6 months post-randomization. Blood pressure will be evaluated using 24-hours monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure differences similar to primary outcome</measure>
    <time_frame>1 year, 2 years, 3 years</time_frame>
    <description>Systolic and Diastolic BP differences (comparison between baseline and evaluated time period) will be measured using 24-hours monitoring and also at office.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood laboratory parameters and renal function</measure>
    <time_frame>6 months, 1, 2, 3 years</time_frame>
    <description>changes in blood concentrations of renin, aldosterone, metanephrines and renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-denervation renal anatomy assessment</measure>
    <time_frame>1 year</time_frame>
    <description>CT angiography will be performed 1 year after RDN</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Hypertension</condition>
  <condition>Resistant to Conventional Therapy</condition>
  <arm_group>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation + conventional antihypertensive medical treatment without spironolactone (spironolactone can be taken only if started before randomization)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional antihypertensive treatment including spironolactone (if not contraindicated).
One year after randomization, renal denervation can be performed according to the physician's decision based on the BP levels and if patient desires the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal denervation (Symplicity® Catheter System™)</intervention_name>
    <description>4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)</description>
    <arm_group_label>Renal denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory hypertension with office SBP &gt; 140 mmHg

          -  SBP &gt; 130 during 24-hours Holter blood pressure monitoring

          -  Treatment with the least 3 antihypertensive medications including diuretics in optimal
             doses

          -  Age &gt; 18 years

          -  Signed informed consent

        Exclusion Criteria:

          -  Secondary forms of hypertension

          -  Chronic renal disease (serum creatinine &gt; 200 umol/l)

          -  Pregnancy

          -  History of myocardial infarction or stroke in last 6 months

          -  Severe valvular stenotic disease

          -  Anatomic abnormalities and variants of renal artery including aneurysms, severe
             stenosis, reference diameter &lt; 4 mm or length &lt; 20 mm

          -  Increased bleeding risk (thrombocytopenia &lt; 50, INR &gt; 1.5)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Widimsky, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiri Widimsky, Prof.MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>General University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiocenter, University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiri Widimsky</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiocenter Podlesi</name>
      <address>
        <city>Trinec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Petr Widimsky, MD</investigator_full_name>
    <investigator_title>Head of Cardiocenter, 3rd Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>Renal denervation</keyword>
  <keyword>Resistant hypertension</keyword>
  <keyword>Spironolactone</keyword>
  <keyword>Long-term Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

